Anti-inflammatory effects of *Saccharomyces boulardii* mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis

Saskia Thomas,¹ Diana Metzke,¹ Jürgen Schmitz,² Yvonne Dörfel,¹ and Daniel C. Baumgart¹

¹Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical Center-Virchow Hospital, Medical School of the Humboldt-University of Berlin, Berlin; and ²Miltenyi Biotec, Research and Development, Bergisch-Gladbach, Germany

Submitted 3 June 2011; accepted in final form 1 September 2011

**Anti-inflammatory effects of *Saccharomyces boulardii*** mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis. *Am J Physiol Gastrointest Liver Physiol* 301: G1083–G1092, 2011. First published September 8, 2011; doi:10.1152/ajpgi.00217.2011.—*Saccharomyces boulardii* (*Sb*) is a probiotic yeast that has demonstrated efficacy in pilot studies in patients with inflammatory bowel disease (IBD). Microbial antigen handling by dendritic cells (DC) is believed to be of critical importance for immunity and tolerance in IBD. The aim was to characterize the effects of *Sb* on DC from IBD patients. Highly purified (>95%), lipopolysaccharide-stimulated CD11c⁺CD123⁻ myeloid DC (mDC) from patients with ulcerative colitis (UC; *n* = 36), Crohn’s disease (CD; *n* = 26), or infectious controls (IC; *n* = 4) were cultured in the presence or absence of fungal supernatant from *Sb* (*SbS*). Phenotype and cytokine production and/or secretion of IBD mDC were measured by flow cytometry and cytokmetric bead arrays, respectively. T cell phenotype and proliferation were assessed in a mixed lymphocyte reaction (MLR) with allogenic CD4⁺CD45RA⁺ naïve T cells from healthy donors. Mucosal healing was investigated in epithelial wound and migration assays with IEC-6 cells. *SbS* significantly decreased the frequency of CD40⁺, CD80⁺, and CD197 (CCR7; chemokine receptor-7) expressing IBD mDC and reduced their secretion of tumor necrosis factor (TNF-α and interleukin (IL)-6 while increasing IL-8. In the MLR, *SbS* significantly inhibited T cell proliferation induced by IBD mDC. Moreover, *SbS* inhibited TGF-β1 (TNF-α and interferon-γ) polarization induced by UC mDC and promoted IL-8 and transforming growth factor-β-dependent mucosal healing. In summary, we provide novel evidence of synergistic mechanisms how *Sb* controls inflammation (inhibition of T cell costimulation and inflammation-associated migration and mobilization of DC) and promotes epithelial restitution relevant in IBD.

LYOPHILIZED *Saccharomyces boulardii* (*Sb*) is a probiotic yeast preparation. Preliminary studies have evaluated the effect of *Sb* in patients with inflammatory bowel disease (IBD). One study of patients suffering from Crohn’s disease (CD) with moderate activity found that the addition of *Sb* to conventional treatment significantly reduced stool frequency (30). A beneficial effect in the maintenance of remission in CD has been reported as well (44). In another pilot study, *Sb* significantly improved the clinical activity index of patients with left-sided ulcerative colitis (UC) when added to their maintenance regimen with mesalazine (29). While well studied in infectious diarrhea, little is known about the mechanisms how *Sb* may control inflammation in CD and UC.

Dendritic cells (DC) are thought to be critically involved in inflammatory T cell polarization and activation observed in human IBD (3, 62). Our group has recently demonstrated a striking correlation between DC subsets and disease activity and aberrant response of myeloid dendritic cells (mDC) to lipopolysaccharide (LPS) (4). Here, we report novel anti-inflammatory effects of *Sb* on primary human mDC from patients with IBD.

**MATERIALS AND METHODS**

**Patients and Controls**

Peripheral blood was obtained from patients with CD, UC, and infectious controls (patients with infectious diarrhea) (IC) seen at our IBD Center; CD and UC patients were characterized according to the Montreal Classification (51). Two validated scores, the modified Truelove Witts Severity Index (MTWSI) for UC and the Harvey Bradshaw Severity Index (HBSI) for CD, were used to assess disease activity (20). UC patients who scored ≥10 on the MTWSI and CD patients who scored ≥7 on the HBSI were classified as having active disease (flare up) (Table 1). Samples were exclusively analyzed from carefully selected patients off steroids, biologics, immunomodulators, and immunosuppressants. The study protocol was approved by Charité’s institutional review board. All patients gave informed written consent to the study.

**Purification of mDC**

Peripheral blood mononuclear cells (PBMC) were isolated from blood samples using a protocol published previously (4). In brief, mDC were isolated by magnetic cell separation from PBMC using CD1c (BDCA-1) antibodies and MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) (24). In blood, the CD1c (BDCA-1) antigen is expressed specifically on DC, which are CD11c⁺CD123⁻. Additionally, a subset of B cells also expresses this antigen. Thus, depletion of B cells with CD19 MicroBeads was required before the enrichment of CD1c (BDCA-1) mDC. The purity of isolated mDC populations was checked by fluorescence-activated cell sorter (FACS) analysis, and samples with <95% mDC were discarded.

**Purification of naïve T cells**

Naïve T cells were isolated by magnetic cell separation from PBMC using the CD4 MultiSort Kit and CD45RA MicroBeads (Miltenyi Biotec) (24). In brief, CD4⁺ cells were positive selected with CD4 MultiSort MicroBeads. Afterward, magnetic particles were enzymatically released, which allows a second magnetic labeling and separation of the cells using CD45RA MicroBeads. CD4⁺CD45RA⁺ cells were positively selected from the preselected CD4⁺ cells. The purity of the isolated naïve T cell population was checked with FACS, and samples with <95% CD4⁺CD45RA⁺ T cells were discarded.
Preparation of Sb Supernatant

Lyophilized Sb was provided by Laboratories Biocodex (Montrouge, France). Sb supernatant (SbS) was prepared as described previously (16, 59). In brief, Sb was cultured in RPMI 1640 cell culture medium for 24 h at 37°C in an initial concentration of 100 mg/ml. To separate the yeast from the supernatant, a 0.2-μm sterile filter (Fisher Scientific, Schwerte, Germany) was used. Previous work from our group (including serial dilutions) indicates that any dilution above 1:2 is not toxic (the viability does not differ between 1:8 and 1:32), and a dilution of 1:8 is most effective and was thus used throughout all experiments (59).

Culture and Stimulation of mDC

Highly purified mDC were cultured for 21 h in RPMI with 0.2% L-glutamine (GIBCO, New York, NY) + 10% human serum type AB (Cambrex, Charles City, IA), + 1% penicillin-streptomycin (GIBCO). To mimic bacterial microbial activation, mDC were stimulated with LPS, a prototypical microbial antigen they may encounter in the gut (35), in the presence or absence of SbS. Ultrapure LPS from Escherichia coli 055:B5 (Calbiochem, Darmstadt, Germany) was added at a concentration of 100 ng/ml (31). Finally, mDC were harvested and stained with the appropriate antibodies to measure the expression of costimulatory molecules by FACS. Supernatants were collected to measure cytokine secretion. Because of the limited cell numbers that can be obtained from one patient, not all experiments were performed in each individual patient.

Mixed Lymphocyte Reaction of mDC and Naïve T Cells

For mixed lymphocyte reaction (MLR) experiments, 1 × 10⁶ highly purified mDC were preincubated with LPS (12.5 mg/ml) in the presence or absence of SbS (see SbS fractionation above) for 3 h at 37°C and 5% CO₂ in RPMI with 0.2% L-glutamine (GIBCO) + 10% human serum type AB (Cambrex) + 1% penicillin-streptomycin (GIBCO). Naïve, allogenic T cells (1 × 10⁶) from healthy volunteers were added and cocultured for 5 days at 37°C and 5% CO₂. To rule out T cell unresponsiveness, staphylococcal enterotoxin B was added out T cell unresponsiveness, staphylococcal enterotoxin B was added.

Mixed Lymphocyte Reaction of mDC and Naïve T Cells

A prototype microbial antigen they may encounter in the gut (35), in the presence or absence of SbS. Ultrapure LPS from Escherichia coli 055:B5 (Calbiochem, Darmstadt, Germany) was added at a concentration of 100 ng/ml (31). Finally, mDC were harvested and stained with the appropriate antibodies to measure the expression of costimulatory molecules by FACS. Supernatants were collected to measure cytokine secretion. Because of the limited cell numbers that can be obtained from one patient, not all experiments were performed in each individual patient.

Mixed Lymphocyte Reaction of mDC and Naïve T Cells

For mixed lymphocyte reaction (MLR) experiments, 1 × 10⁶ highly purified mDC were preincubated with LPS (12.5 mg/ml) in the presence or absence of SbS (see SbS fractionation above) for 3 h at 37°C and 5% CO₂ in RPMI with 0.2% L-glutamine (GIBCO) + 10% human serum type AB (Cambrex) + 1% penicillin-streptomycin (GIBCO). Naïve, allogenic T cells (1 × 10⁶) from healthy volunteers were added and cocultured for 5 days at 37°C and 5% CO₂. To rule out T cell unresponsiveness, staphylococcal enterotoxin B was added out T cell unresponsiveness, staphylococcal enterotoxin B was added.

Preparation of Sb Supernatant

Lyophilized Sb was provided by Laboratories Biocodex (Montrouge, France). Sb supernatant (SbS) was prepared as described previously (16, 59). In brief, Sb was cultured in RPMI 1640 cell culture medium for 24 h at 37°C in an initial concentration of 100 mg/ml. To separate the yeast from the supernatant, a 0.2-μm sterile filter (Fisher Scientific, Schwerte, Germany) was used. Previous work from our group (including serial dilutions) indicates that any dilution above 1:2 is not toxic (the viability does not differ between 1:8 and 1:32), and a dilution of 1:8 is most effective and was thus used throughout all experiments (59).

Preparation of Sb Supernatant

Lyophilized Sb was provided by Laboratories Biocodex (Montrouge, France). Sb supernatant (SbS) was prepared as described previously (16, 59). In brief, Sb was cultured in RPMI 1640 cell culture medium for 24 h at 37°C in an initial concentration of 100 mg/ml. To separate the yeast from the supernatant, a 0.2-μm sterile filter (Fisher Scientific, Schwerte, Germany) was used. Previous work from our group (including serial dilutions) indicates that any dilution above 1:2 is not toxic (the viability does not differ between 1:8 and 1:32), and a dilution of 1:8 is most effective and was thus used throughout all experiments (59).

Preparation of Sb Supernatant

Lyophilized Sb was provided by Laboratories Biocodex (Montrouge, France). Sb supernatant (SbS) was prepared as described previously (16, 59). In brief, Sb was cultured in RPMI 1640 cell culture medium for 24 h at 37°C in an initial concentration of 100 mg/ml. To separate the yeast from the supernatant, a 0.2-μm sterile filter (Fisher Scientific, Schwerte, Germany) was used. Previous work from our group (including serial dilutions) indicates that any dilution above 1:2 is not toxic (the viability does not differ between 1:8 and 1:32), and a dilution of 1:8 is most effective and was thus used throughout all experiments (59).
RESULTS

SbS Decreases the Number of CD40- and CD80-Expressing LPS-Stimulated mDC

First, we studied the expression of CD40 and CD80, two costimulatory molecules that are known to be upregulated on activated human mDC and critical for the activation of naïve T cells (15, 41, 63). After stimulation with LPS and incubation for 21 h in the presence or absence of SbS, mDC were stained for CD40 and CD80 and eventually analyzed by flow cytomtery (Fig. 1).

As expected, LPS induced a substantial expression of CD40-positive cells in remission (CD 93.61 ± 0.5%) (UC 87.58 ± 2.05%) and acute flare ups (CD 89.69 ± 5.0%) (UC 92.33%). However, addition of SbS to these cultures significantly (except for UC flare up) decreased the percentage of CD40-expressing mDC in remission (CD 47.58 ± 4.38%, P < 0.01) (UC 56.48 ± 3.91%, P < 0.001) and acute flare ups (CD 49.47 ± 8.01%, P < 0.05) (UC 40.20 ± 10.93%). (Fig. 1, A and C).

The same trend was observed for CD80, where LPS also induced a substantial expression of CD80-positive cells in remission (CD 92.35 ± 0.1%) (UC 92.57 ± 1.4%) and acute flare ups (CD 92.77 ± 2.3%) (UC 95.93%). As for CD40, addition of SbS to these cultures significantly decreased the fraction of CD80-expressing mDC and remission (CD 59.09 ± 7.2%, P < 0.05) (UC 65.70 ± 5.0%, P < 0.01) and acute flare ups (58.35 ± 5.8%, P < 0.01) (UC 43.52 ± 10.0%) (Fig. 1B).

The SbS effects on mDC isolated from IC (IC CD40 93.64 ± 0.44 vs. 56.54 ± 2.3%, P < 0.001) (IC CD80 96.95 ± 0.5 vs. 64.88 ± 1.0%, P < 0.001) were comparable (Fig. 1, B and C). Overall, the inhibitory effect of SbS was comparable in mDC isolated from UC and CD patients, as well as in IC.

SbS Decreases the Number of CD197 (CCR7)-Expressing LPS-Stimulated mDC

CCR7 is not only another maturation marker for DC, but also involved in the steady-state and inflammation-associated migration and mobilization of DC and T cells (25). LPS induced an expression of CCR7 by virtually all mDC-positive cells in remission (CD 96.09 ± 1.4%) (UC 95.68 ± 1.0%) and flare ups (CD flare up 95.14 ± 2.7%) (98.71%) (Fig. 2).

However, addition of SbS to these cultures decreased the percentage of CCR7-expressing mDC in remission (CD 73.47 ± 4.2%, P < 0.05) (UC 75.68 ± 2.7%, P < 0.001) and acute CD flare ups (CD 80.74 ± 3.5%, P < 0.05). The trend for flare ups (UC 86.12 ± 3.1%) did not reach statistical significance.

The SbS effects on mDC isolated from IC (IC 98.62 ± 0.2 vs. 88.07 ± 3.5%, P < 0.05) were comparable (Fig. 2).

There were no significant differences between the numbers of CD83- and CD86-expressing mDC (data not shown).

SbS Impact on Cytokine Secretion by LPS-Stimulated mDC

To further investigate the cytokine secretion by LPS-stimulated mDC in the presence or absence of SbS, we analyzed the culture supernatants. TNF-α, IL-6, and IL-8 were assessed.

TNF-α. The secretion of TNF-α by LPS-stimulated mDC from UC patients in remission (UC remission 315.9 ± 42.3 vs. 118.8 ± 35.9 pg/ml P < 0.01) was significantly reduced when SbS was added to the culture. The secretion of TNF-α by
LPS-stimulated mDC from flaring (UC flare up 355.5 ± 80 vs. 255.6 ± 99.7 pg/ml) and CD (CD flare up 197.6 ± 60 vs. 102.5 ± 25 pg/ml) patients as well as IC (IC 323.5 ± 72.2 vs. 296.5 ± 50 pg/ml) was decreased, but these trends did not reach statistical significance (probably because of low patient numbers). There was no difference seen in CD patients (CD remission 193.1 ± 32.6 vs. 191 ± 55 pg/ml) in remission (Fig. 3A).

IL-6. The secretion of IL-6 by LPS-stimulated mDC from UC patients (UC remission 2,022 ± 578 vs. 1,198 ± 337 pg/ml) and CD patients (CD remission 1,355 ± 225.3 vs. 1,037 ± 302 pg/ml) in remission as well as flaring (UC flare up 3,084 ± 766 vs. 2,109 ± 696.4 pg/ml) and CD (CD flare up 2,637 ± 539.1 vs. 2,102 ± 509 pg/ml) patients decreased when SbS was added to the culture but did not reach statistical significance. A similar trend was seen with IC (IC 3,175 ± 40.3 vs. 2,355 ± 626 pg/ml) (Fig. 3B).

SbS Augments the Secretion of IL-8

The secretion of IL-8 by LPS-stimulated mDC from IBD patients in remission (CD remission 70,377 ± 5,699 pg/ml, UC remission 76,914 ± 14,503 pg/ml) and flare up (CD flare up 63,574 ± 8,081 pg/ml, UC flare up 73,473 ± 11,201 pg/ml) increased significantly (CD remission 174,392 ± 13,780 pg/ml, P < 0.001; UC remission 163,460 ± 11,578 pg/ml, P < 0.001; CD flare up 165,301 ± 15,770 pg/ml, P < 0.001; UC flare up 164,783 ± 23,685 pg/ml, P < 0.01) when SbS was added to the culture. A similar secretion pattern was seen in IC (IC 84,031 ± 2,970 vs. 192,890 ± 18,237 pg/ml) but could not be statistically evaluated because of low patient numbers (see MATERIALS AND METHODS). (Fig. 3C).

SbS Inhibits mDC-Induced T Cell Proliferation in an Allogenic MLR

Because the first set of experiments suggested an effect of SbS on costimulatory molecules and DC maturation markers highly relevant for T cell activation, we decided to investigate its direct effect on T cell proliferation and phenotype (see below). We studied the effect in an allogenic MLR of naïve T cells and mDC.

Naïve T cells showed almost no autoproliferation after stimulation with LPS alone (2.47 ± 1.21%). However, in an allogenic MLR with LPS, stimulated mDC induced a robust proliferation in IBD (CD remission 45.6 ± 1.1%, CD flare up 44.24 ± 5.3%) and UC (UC remission 38.64 ± 5.2%, UC flare up 23.11 ± 1.9%). Addition of SbS significantly reduced T cell proliferation in patients with IBD (CD remission 27.77 ± 1.0%, P < 0.01; CD flare up 30.02 ± 7.7%; UC remission 18.03 ± 5.3%, P < 0.05; UC flare up 5.2 ± 1.8%, P < 0.001). The effects of SbS were most striking in UC (Fig. 4).

SbS Induces an Anti-Inflammatory T Cell Phenotype in MLR With UC mDC

To further characterize the impact of SbS-exposed mDC on T cells, the cells from the previous MLR experiments were restimulated and phenotyped. Moreover, culture supernatants were analyzed for key proinflammatory cytokines TNF-α, IL-12/23p40, and IL-17, and the epithelial cell restitution and would healing promoting cytokine TGF-β were measured by CBA.
Intracellular TNF-α production (Fig. 5A) in proliferating T cells decreased significantly in MLR experiments with LPS-stimulated mDC isolated from UC patients (62.13 ± 2.4 vs. 34.05 ± 10.2%, P < 0.05) in acute flare ups when SbS was added to the approach, but not during remission (data now shown). A similar trend was seen for IFN-γ (Fig. 5B). Its production in proliferating T cells decreased in MLR experiments with mDC isolated from UC patients (31.14 ± 3.5% vs. 19.71 ± 6.7%) in acute flare ups but not remission (data not shown). These effects were restricted to UC and were not seen with mDC from CD patients.

TGF-β. The secretion of TGF-β in MLR culture supernatants by LPS-stimulated mDC from UC patients in remission (UC remission 79.8 ± 26.6 vs. 136.4 ± 22.2 pg/ml) and flare up (UC flare up 55.6 ± 4.3 vs. 127.3 ± 36 pg/ml) increased when SbS was added. This effect was also seen in CD patients in remission (CD remission 64.7 ± 21.3 vs. 127.5 ± 25.8 pg/ml) when SbS was added but not in flare ups (CD flare up 59.1 ± 44.7 vs. 63.7 ± 30.1 pg/ml). (Fig. 5C).

There was virtually no IL-12/23p40 or IL-17 secretion by T cells in the MLR detectable (data not shown).

SbS-Induced Cytokines Promote Wound Healing in an Epithelial Cell Injury Model

To verify the functional relevance of the increased IL-8 and TGF-β concentrations in SbS-exposed cultures or cocultures, we studied their effect in an epithelial cell injury model. The number of migrating epithelial cells in IL-8 (335 ± 16 cells)- or TGF-β (296 ± 5 cells)-treated cultures was significantly (P < 0.001 vs. P < 0.05, respectively) higher compared with medium (255 ± 14 cells). While SbS may have an (statistically not significant) intrinsic effect on migration, the data suggest it is predominantly mediated through interaction with mDC and/or T cells and the resulting cytokines IL-8 and TGF-β (Fig. 6).

DISCUSSION

The underlying mechanisms of Sb’s potential therapeutic efficacy in IBD compared with other diarrheal illnesses have not been systematically investigated in humans (17). Because of the long-standing use of Sb in infectious diarrhea, most experimental research from in vitro studies with organoid or

Fig. 3. SbS impact on cytokine secretion of LPS-stimulated mDC. Adding SbS to LPS-stimulated mDC decreased the secretion of tumor necrosis factor (TNF)-α (A) and interleukin (IL)-6 (B) and increased the secretion of epithelial cell restitution (mucosal healing) and wound closure promoting IL-8 (C). Bars represent means ± SE.
cell cultures and animal models have focused on the prevention of microbial pathogen adherence (46, 58), translocation of the commensal microbial flora (8, 26), investigation of neutralization of bacterial toxins [i.e., *Clostridium difficile* toxin A (14, 16, 45) or *Cholera* toxin (9)], toxin-related signaling (9, 18, 19), maintenance of normal intestinal permeability and barrier function (45), as well as control of mucosal electrolyte transport and luminal secretion (16, 27, 28, 45, 50).

However, a positive outcome in preliminary clinical studies in IBD (29, 30, 44) and beneficial effects of *Sb* in immunological (adoptive transfer model in SCID mice) and chemical (DSS colitis) (21, 36) animal models of IBD imply additional efficacy and anti-inflammatory mechanisms in CD and UC.

Our study demonstrates for the first time that *Sb* controls DC maturation, T cell activation, production and secretion of cytokines critically relevant for T cell phenotype, T cell polarization, and epithelial cell restitution (mucosal healing) in patients with CD and UC and also infectious colitis.

An important prerequisite for T cell activation is the expression of costimulatory molecules on antigen-presenting cells such as DC (43). Their upregulation on the cell surface marks not only a phenotypic but substantial functional change from being inducers of peripheral tolerance to potent activators of immune effector cells, such as T cells (52, 53). We first investigated the expression of CD40 and CD80 on mDC from IC and IBD patients with or without the presence of *Sb*. Here, we decided to use the microbial antigen surrogate motif and model TLR ligand LPS to prime mDC, since this mimics the situation these cells may encounter in the gut. Consistent with the available literature, freshly isolated, i.e., immature and inactive, mDC expressed practically no detectable numbers of the two activation markers (data not shown) (40). Exposure to LPS induced the expected maturation of DC as indicated by their increased expression of costimulators. However, when cultured in the presence of *SbS*, substantially fewer mDC express CD40 and CD80.

CD197 (CCR7)-mediated signals control the migration of immune cells to secondary lymphoid organs and subsequently their positioning within defined functional compartments (25). The *SbS*-dependent reduced expression of CD197 in mDC observed by us may prevent their migration from the peripheral circulation to the sites of inflammation, i.e., the gut in IBD (4, 5).

The effects of *SbS* on mDC were not restricted to phenotypic changes but paralleled by functional consequences, since we were able to demonstrate that *SbS* suppresses LPS-stimulated mDC to secrete less TNF-α and IL-6. An increased secretion of these prototypical inflammatory cytokines upon contact with microbial antigens encountered in the gut, such as LPS, polarizes T cells toward a proinflammatory phenotype (Th1) and contributes to the perpetuation of inflammation known to occur in IBD (3, 62). Approved and investigational drugs individually targeting these important IBD cytokines are available and clinically effective (34, 57). We show that *Sb* can block the secretion of both. Moreover, *SbS* suppresses LPS-stimulated mDC-mediated T cell proliferation in an allogenic MLR and polarizes naïve T cells from flaring UC patients to acquire an anti-inflammatory phenotype. These data are in line with previous research reporting that *Sb* blocks TNF-α gene expression and secretion by lymphoid and nonlymphoid cells (1, 22, 22, 23, 23).

In addition to these direct anti-inflammatory effects, *Sb* increased the secretion of TGF-β and IL-8. TGF-β has been not only attributed to the polarization of naïve T cells to acquire a regulatory phenotype but also in epithelial restitution and would healing (2, 7). While IL-8 is mostly known as a chemotactic agent for innate immune cells, very recent research indicates that IL-8 is a critical regulator of angiogenesis, cell migration, and other wound-closure mechanisms, ultimately resulting in mucosal healing (33, 42, 48, 64). Interestingly, similar effects have been recently demonstrated with supernatants of a bacterial species, where the intestinal wound-healing effects were also IL-8-dependent and even facilitated recovery of experimental colitis as shown by increased body weight and reduced rectal bleeding and histological severity (33). Thus, the perhaps initially paradoxically seeming increased IL-8 secretion may be in fact a synergistic wound-healing effect induced by *Sb*.

Fig. 4. *SbS* inhibits T cell (TC) activation and proliferation in an allogenic mixed lymphocyte reaction (MLR) with mDC. A: MLR of mDC and naïve T cells. mDC from IBD patients were preincubated with LPS in the presence or absence of *SbS* for 3 h. Carboxyfluorescein-diacetate-succinimidylester (CFSE)-labeled allogenic T cells from healthy volunteers were added and cocultured for 5 days. Data from these experiments are summarized in bar graphs. Bars represent means ± SE. Statistical significance: *P < 0.05, **P < 0.01, and ***P < 0.001. B: FACS plots from representative experiments show proliferation assessed by CFSE staining.
Previous work of our group suggests that the active component has a molecular weight smaller than \(<3\) kDa. This implies that wall compounds of \(Sb\) such as glycoproteins or glycolipids may be responsible for the observed effects (37). Our current study was restricted to the investigation of primarily humoral factors of \(Sb\). The anti-inflammatory effects of \(Sb\) are probably not limited to secreted compound(s) found in the supernatant but may also involve cellular wall compounds and/or their synergistic (interaction). To better understand the cellular mechanisms of \(Sb\)’s interaction with mDC, the three principal fungal wall compound groups \(\beta\)-glucans, mannoproteins, and chitin and their respective receptors (TLR2, TLR4, Dectin-1, DC-SIGN, MR, CR, and others) and signaling pathways as well as comparison with related and unrelated species such as \(Saccharomyces cerevisiae\) and \(Candida albicans\), respectively, is necessary and subject of ongoing research in our laboratory. Recent research in mice (61) and humans (32) indicates that myeloid-derived cells may have a role in desensitizing immune responses, since long-term NOD2 stimulation of macrophages significantly decreased production of proinflammatory cytokines, and this phenomenon is disturbed in mutant macrophages from CD patients (32) (discussed in Ref. 55). It remains to be studied whether this phenomenon may also relate to the observed effect of \(Sb\) on human mDC.

Our study has additional limitations. To the best of our knowledge, it is unknown (unstudied) what the actual distri-
bution of the lyophilized pharmacological yeast product and more specifically their humoral components throughout the human intestine is or their concentration at the individual epithelial cell level. We based our supernatant concentrations and dilutions on the work of other investigators (14, 16) and our own dilution series (59) and know that they are at least not toxic (see above).

We cannot rule out that SbS-induced downregulation of co-stimulatory molecules on LPS-stimulated mDC is partially mediated through direct effects of SbS on LPS itself. One study in an animal model identified in Sb a protein phosphatase that had a greater ability to dephosphorylate LPS of E. coli, which when injected in rats produced substantially less TNF-α and no organic lesions compared with the non-Sb-exposed LPS (11, 12). However, this observation would not explain the other novel immunological and epithelial restitution effects demonstrated by us.

Additional evidence for a modulation of the immune response by Sb to explain its clinical benefit in inflammatory and...

Fig. 6. SbS promotes epithelial restitution (mucosal healing) in an injury model. Confluent monolayer wounding assays: epithelial cell migration was evaluated by enumerating IEC-6 cells across the injury border in a standardized wound area. The number of migrating epithelial cells in IL-8, but also TGF-β-treated monolayers, was significantly higher compared with medium. While SbS may have an (statistically not significant) intrinsic effect on migration, the data suggest it is predominantly mediated through interaction with mDC and/or T cells and the resulting cytokines. A: summary bar chart. Bars represent means ± SE. Statistical significance: **P < 0.01, and ***P < 0.001. B: representative images of exemplary experiments.

Fig. 7. Cartoon depicting proposed novel mechanism of action of SbS.
infectious conditions comes from in vitro and animal studies. Orally administered Sb was shown to increase the production of secretory IgA and the secretory component of immunoglobulins in growing rats and monoassociated germ-free mice, thereby augmenting the host’s first line of defense of the innate immune system in the gut (10, 47).

In summary, we provide novel evidence of synergistic mechanisms of Sb to control inflammation and promote epithelial restitution relevant to IBD, but also infectious colitis (Fig. 7). Because the effects of Sb were most prominent in UC, it may be worthwhile to study its potential efficacy in patients with further well-designed clinical trials and additional translational research studies.

GRANTS
This work was supported by unrestricted research grants of the Eli and Edythe L. Broad Foundation, Los Angeles, CA and Laboratoires Biocodex, Gentilly, France and by a Charité bonus grant award to D. C. Baumgart.

DISCLOSURES
None of the funders had any influence on the conduction of the experiments, analysis of the data or interpretation of the results.

REFERENCES
SACCHAROMYCES BOULARDII MODULATES DENDRITIC CELLS IN IBD